Home
    Disclaimer
    25CN-NBOH molecular structure

    25CN-NBOH Stats & Data

    Nboh-2c-cn
    Chemical Class Phenethylamine
    Psychoactive Class Psychedelic
    Half-Life Human t½ unknown; rodent plasma t½ ≈ 3 – 5 h (extrapolated)

    Pharmacology

    DrugBank
    State Solid

    Description

    25CN-NBOH (N-(2-hydroxybenzyl)-2,5-dimethoxy-4-cyanophenylethylamine) is a newly developed selective 5-HT2A agonist. It has been tested with regard to the head-twitch-response (HTR) model of 5-HT2A activity and effects on locomotion . It was discovered in 2014 at the University of Copenhagen.

    Mechanism of Action

    25CN-NBOH is one of the most selective agonist ligands for the 5-HT2A receptor discovered. It has a pKi of 8.88 at the human 5-HT2A receptor and is 100x more selective for 5-HT2A over 5-HT2C, and 46x more selective for 5-HT2A over 5-HT2B .

    Effect Profile

    Curated
    Psychedelic 5.0

    Strong body load with moderate visuals, mild headspace and auditory effects

    Visual Intensity×3
    7
    Headspace Depth×3
    5
    Auditory Effects×1
    4
    Body Load / Somatic Effects×1
    10

    Tolerance & Pharmacokinetics

    drugs.wiki
    Half-Life
    Human t½ unknown; rodent plasma t½ ≈ 3 – 5 h (extrapolated)
    Addiction Potential
    Very low; no compulsive redosing reported, tolerance develops rapidly after one session.

    Cross-Tolerances

    psychedelic phenethylamines
    60% ●○○
    tryptamines
    50% ●○○
    lysergamides
    60% ●○○

    Harm Reduction

    drugs.wiki

    • Misrepresentation: NBOH/NBOMe blotters have repeatedly been sold as LSD; microgram doses plus uneven laying raise overdose risk. Do not assume unknown blotter is LSD; use reagents and drug checking when available. • Testing: Use indole‑detecting reagents (Ehrlich or Hofmann) to confirm lysergamide; Marquis does not react with LSD but can show reactions with many NBOMe/NBOH—use both types to discriminate. UV fluorescence can help (LSD fluoresces; NBOMe/NBOH often do not). • Oral ‘inactivity’ myth: Swallowing NBOH/NBOMe is not a reliable way to avoid effects; oral activity is variable. Treat any unknown blotter as potentially active when swallowed. • Volumetric dosing: Never eyeball powder or highly concentrated solutions. For any handling beyond pre‑laid blotters, pre‑dilute to a known µg/mL and measure by volume; avoid powder insufflation because typical milligram scales cannot resolve safe microgram doses. • Intranasal caution: Faster onset but more adverse effects; cluster reports with 25B‑NBOH include status epilepticus following insufflation. Prefer transmucosal over intranasal and avoid powders. • Cardiovascular strain: Vasoconstriction and tachycardia are common; combining with stimulants or vasoconstrictive decongestants increases risk. Screen for personal/family cardiovascular disease and hydrate, keep cool, and avoid redosing. • Lithium: Psychedelics plus lithium have repeatedly been linked to seizures and medical emergencies; avoid entirely. • Tramadol: Lowers seizure threshold and has produced seizures in combinations with other psychoactives; avoid. • Synergy with LSD/other psychedelics: Users report extreme potentiation; do not combine on a first exposure. Cross‑tolerance can still leave side‑effect risk at similar doses. • HPPD risk: NBOMe/NBOH use is anecdotally associated with a relatively higher incidence of lingering visual phenomena; minimize frequency, dose, and avoid sleep deprivation. • Storage/handling: Protect blotters/solutions from heat and light; label clearly to prevent accidental ingestion by others. Case anecdotes describe severe outcomes after accidental dosing from mislabeled bottles.

    ← Back to 25CN-NBOH